Recce Pharmaceuticals Ltd

A$0.33As of Sun 8 Nov 2026, 12:00 UTC
ASX:RCEHealthcare
Country Australia
PE (Fwd) •••
TSR 10Y CAGR 6.74%
Div yield —
ROE —
Biotechnology
Beta (5Y) 0.50
PE TTM —
TSR TTM (22.35%)
Mkt cap A$100.9M
ROIC (1207.75%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.399
21.01%
(61.99%)
Hold 0|11|3|5|8
2Q26
3Q26
4Q26
1Q27
Earnings per share$
—
—
—
—
(0.87%)
(0.98%)
(3.42%)
(3.15%)
Revenue$M
4.680
4.667
4.758
4.710
2.60%
3.46%
3.97%
0.72%
Peers (US$69.30M)
Cap (US$)
PE
84.53M
—
52.58M
—
Capital
TTM
5Y
10Y
Leveragex
0.616
(1.647)
(1.514)
EBIT/Intx
1.088
0.344
0.396
Own earn%
1169.31
21.54
37.36
Sh yield%
39.58
49.32
44.94
Owners
Insiders/Inst%
3.73
46.96
Short interest%
2.53
SBC / revenue%
1.86
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
22–31
$1 testx
0.0
Incr. ROIC%
6